Thereafter, anti-PD-1 mAbs such as pembrolizumab, nivolumab, cemiplimab and as well as anti-PD-L1 mAbs such as atezolizumab, avelumab, durvalumab, have been used to treat patients with cancer, especially in locally advanced and metastatic settings (Qin et al., 2019; Vaddepally et al., 2020). Here, CD274 is linked to cancer.